MeSH D030342 - inborn genetic diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009358:Hereditary congenital and neonatal diseases and abnormalities
0 Companies
0 Drugs
Success rate
D030342:
Inborn genetic diseases
D000071070:Familial multiple lipomatosis
0 Companies
0 Drugs
Success rate
D000072661:Ciliopathies
0 Companies
0 Drugs
Success rate
D000077428:Gata2 deficiency
0 Companies
0 Drugs
Success rate
D000081207:Primary immunodeficiency diseases
D000083083:Laminopathies
D000312:Congenital adrenal hyperplasia
D000699:Congenital pain insensitivity
0 Companies
0 Drugs
Success rate
D000745:Hemolytic anemia congenital
0 Companies
0 Drugs
Success rate
D001260:Ataxia telangiectasia
0 Companies
0 Drugs
Success rate
D002636:Cherubism
0 Companies
0 Drugs
Success rate
D003550:Cystic fibrosis
D003966:Camurati-engelmann syndrome
0 Companies
0 Drugs
Success rate
D004392:Dwarfism
D006453:Hemoglobinopathies
0 Companies
0 Drugs
Success rate
D007619:Kartagener syndrome
0 Companies
0 Drugs
Success rate
D008382:Marfan syndrome
0 Companies
0 Drugs
Success rate
D008661:Inborn errors metabolism
D009136:Muscular dystrophies
0 Companies
0 Drugs
Success rate
D009261:Nail-patella syndrome
0 Companies
0 Drugs
Success rate
D009386:Hereditary neoplastic syndromes
0 Companies
0 Drugs
Success rate
D009800:Oculocerebrorenal syndrome
0 Companies
0 Drugs
Success rate
D009958:Orofaciodigital syndromes
0 Companies
0 Drugs
Success rate
D010004:Primary hypertrophic osteoarthropathy
0 Companies
0 Drugs
Success rate
D010009:Osteochondrodysplasias
0 Companies
0 Drugs
Success rate
D010013:Osteogenesis imperfecta
0 Companies
0 Drugs
Success rate
D010381:Pelger-huet anomaly
0 Companies
0 Drugs
Success rate
D012873:Genetic skin diseases
D014898:Werner syndrome
0 Companies
0 Drugs
Success rate
D015499:Inborn errors renal tubular transport
0 Companies
0 Drugs
Success rate
D015785:Hereditary eye diseases
0 Companies
0 Drugs
Success rate
D017436:Kallmann syndrome
0 Companies
0 Drugs
Success rate
D019896:Alpha 1-antitrypsin deficiency
0 Companies
0 Drugs
Success rate
D020271:Nervous system heredodegenerative disorders
0 Companies
0 Drugs
Success rate
D020294:Congenital myasthenic syndromes
0 Companies
0 Drugs
Success rate
D024741:Hypertrophic cardiomyopathy familial
0 Companies
0 Drugs
Success rate
D025063:Chromosome disorders
0 Companies
0 Drugs
Success rate
D025861:Inherited blood coagulation disorders
D029502:Hypoplastic anemia congenital
0 Companies
0 Drugs
Success rate
D031845:Hajdu-cheney syndrome
0 Companies
0 Drugs
Success rate
D040181:X-linked genetic diseases
0 Companies
0 Drugs
Success rate
D046589:Cadasil
0 Companies
0 Drugs
Success rate
D050010:Familial dysalbuminemic hyperthyroxinemia
0 Companies
0 Drugs
Success rate
D050174:Y-linked genetic diseases
0 Companies
0 Drugs
Success rate
D052159:Frasier syndrome
0 Companies
0 Drugs
Success rate
D053306:Hyper-igm immunodeficiency syndrome
0 Companies
0 Drugs
Success rate
D053840:Brugada syndrome
0 Companies
0 Drugs
Success rate
D055947:Loeys-dietz syndrome
0 Companies
0 Drugs
Success rate
D056660:Hereditary autoinflammatory diseases
0 Companies
0 Drugs
Success rate
D056684:Yellow nail syndrome
0 Companies
0 Drugs
Success rate
D056685:Costello syndrome
0 Companies
0 Drugs
Success rate
D056731:Donohue syndrome
0 Companies
0 Drugs
Success rate
D056735:Autoimmune lymphoproliferative syndrome
0 Companies
0 Drugs
Success rate
D058631:Pycnodysostosis
0 Companies
0 Drugs
Success rate
D058747:Charge syndrome
0 Companies
0 Drugs
Success rate
D065768:Lennox gastaut syndrome
D000096803:Imprinting disorders
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| CSL Behring | .alpha.1-proteinase inhibitor human | Respreeza | 2015-08-20 | |||
| Regeneron Pharmaceuticals | Rilonacept | Rilonacept Regeneron (previously Arcalyst) | 2009-10-23 | |||
| Kiniksa Pharmaceuticals | Rilonacept | Arcalyst | 2008-02-27 |
Clinical Trials
Historical Success Rate
Phase 1
14%1/7
Phase 2
17%4/23
Phase 3
25%3/12
Approved: 1Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use